Theralase Technologies Inc. (TSXV:TLT)
0.1550
0.00 (0.00%)
Dec 1, 2025, 1:30 PM EST
Theralase Technologies Revenue
Theralase Technologies had revenue of 279.64K CAD in the quarter ending September 30, 2025, a decrease of -19.32%. This brings the company's revenue in the last twelve months to 1.00M, up 1.46% year-over-year. In the year 2024, Theralase Technologies had annual revenue of 1.03M, down -3.45%.
Revenue (ttm)
1.00M
Revenue Growth
+1.46%
P/S Ratio
39.80
Revenue / Employee
50.05K
Employees
20
Market Cap
39.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.03M | -36.88K | -3.45% |
| Dec 31, 2023 | 1.07M | -68.26K | -6.00% |
| Dec 31, 2022 | 1.14M | 357.93K | 45.85% |
| Dec 31, 2021 | 780.64K | -148.48K | -15.98% |
| Dec 31, 2020 | 929.12K | -34.93K | -3.62% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.78B |
| dentalcorp Holdings | 1.66B |
| Trulieve Cannabis | 1.66B |
| Green Thumb Industries | 1.61B |
| Extendicare | 1.59B |
| WELL Health Technologies | 1.25B |
| Sienna Senior Living | 967.05M |
| Knight Therapeutics | 413.85M |
Theralase Technologies News
- 7 days ago - Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study - Newsfile Corp
- 14 days ago - Theralase(R) Investor Conference Call Reminder - Newsfile Corp
- 21 days ago - Theralase(R) Releases 3Q2025 Financial Statements - Newsfile Corp
- 26 days ago - Q1 2025 Theralase Technologies Inc Earnings Call Transcript - GuruFocus
- 2 months ago - Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus - Newsfile Corp
- 3 months ago - Q2 2025 Theralase Technologies Inc Earnings Call Transcript - GuruFocus
- 3 months ago - Theralase(R) Extends Warrants - Newsfile Corp
- 3 months ago - Theralase(R) Releases 2Q2025 Financial Statements - Newsfile Corp